The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to ...
In recent news, the FDA granted Fast Track designation to remlifanserin (ACP-204; Acadia Pharmaceuticals), an investigational selective serotonin 5-HT2A receptor inverse agonist, for the treatment of ...
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Xenon Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for azetukalner (XEN1101) as adjunctive treatment for focal seizures in adults with epilepsy, based on ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare ...
Foundational health behaviors reduce migraine burden, but frequent or disabling attacks commonly require preventive treatment ...
The American Academy of Neurology (AAN) and American Headache Society (AHS) have issued an updated practice guideline on ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
Subacute neurocognitive decline with multifocal enhancing lesions in immunosuppressed AQP4+ NMOSD warrants evaluation for EBV ...
HIMALAYA was a multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted at 63 sites across 13 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results